PPT-LDL Cholesterol Lowering with

Evolocumab and Outcomes in Patients with Peripheral Artery Disease Insights from the FOURIER Trial Marc P Bonaca Patrice Nault Robert P Giugliano Anthony C Keech Armando Lira Pineda Estella Kanevsky Julia Kuder Sabina A Murphy J . 0. International Atherosclerosis Society, 2013. American Diabetes Association, 2013. European Atherosclerosis Society, 2013. European Society of Cardiology, 2012. National Heart, Lung, and Blood Institute & National Institutes of Health & American Academy of Pediatrics, 2011. Blake Wachter, MD, PhD. Idaho Heart Institute. Epidemiology . 1 billion people (26%) people of the world have HTN. As high as 69 % of men and 73% women. American . Heart Association estimated the direct and indirect costs of high blood pressure in 2010 as $76.6 . and Their Relationship to Health. Mark Pettus MD. Medical Director Functional Formularies. Director Medical Education, Wellness and Population Health. Berkshire . H. ealth Systems. Learning Objectives. NICE –CG 181 Continuum of CVD Risk and its treatment. Post MI/Angina. Other Atherosclerotic Manifestations. Subclinical . Atherosclerosis:. Type 2 diabetes. Multiple RFs. QRISK>10%. Low . Risk. Secondary. Implications of the relationship between risk factor (LDL-C) level and event rate. Risk factor level. Risk factor level. LOG of. event. rate. Event . rate. 1: Is there a continuous relationship?. 2: Is there a lower limit?. Lowering Sodium without Losi ng Flavor Union Public Schools Tulsa, Oklahoma Lisa Griffin, RD, LD Callie Fowler- Farish Director of Child Nutrition District Executive Chef Union Public Schools-Tulsa, OK Rodney D Gilbert. Patient JM. 14 year old girl, presented 06/07/2015. Severe oedema, . hypoalbuminaemia. and proteinuria. Diagnosis nephrotic syndrome. No response to steroids. At Southampton. Cushingoid. Brian A. . Ference. MD, . MPhil. , . MSc. , John J. P. Kastelein MD, PhD, . Kausik. K. Ray MD, . MPhil. , Henry N. Ginsberg MD, M. John Chapman PhD, . DSc. , Chris J. Packard . DSc. , Ulrich . Laufs. . 4. th. Stage . Dr. Dalia . Abd. Al- Kader. PhD Pharmacology. Coronary heart disease . (CHD) . is correlated with elevated levels of low-density lipoprotein cholesterol (LDL-C; “bad” cholesterol) and triglycerides and low levels of high-density lipoprotein cholesterol (HDL-C; “good cholesterol”). . What are the current perspectives?. Prof. . Erik . Stroes. Academic Medical Centre. Amsterdam, The Netherlands. Is There a Therapeutic Need. . Beyond LDL Lowering ?. 1. Heart Protection Study Collaborative Group.. PCSK9 inhibitors. New option for dyslipidemia. Alireza Esteghamati,MD. November 2018. Agenda. Residual risk after Statin. . PCCSK9 Inhibitors physiology & mechanism of action. PCSK-9 Inhibitor trials: . holesterol. When you have your blood it can build up the inner walls of your heart arteries. Over time this forms plaque. Plaque narrows your arteries and puts you at an increased risk for having a Advice f rom the National Lipid Association Clinician’s Lifestyle Modification Toolbox P rovided as part of the Clinician’s Lifestyle Modification Toolbox on Lipid.org. Learn more at LearnYourLi An interpretation of the continuous relationship between LDL-C and CVD. Therefore, many men and . most. women with heart disease have lipid problems other than high total or LDL cholesterol that put them at risk for heart disease. .